arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Skye Bioscience, Inc.

SKYE
$1.80 ▲ +0.09 (+5.26%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
61 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Skye Bioscience, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $71.4M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 2224.9%
FCF / Share $-0.18
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

61-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-12.51M
↓ -12.7%
FCF / Share Free cash flow per share
$-0.18
↑ +16.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 61 quarters